Deerfield Management Company, L.P. (Series C) Merus N.V. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Merus N.V. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 3,408,539 shares of MRUS stock, worth $135 Million. This represents 3.17% of its overall portfolio holdings.
Number of Shares
3,408,539
Previous 2,749,401
23.97%
Holding current value
$135 Million
Previous $163 Million
4.68%
% of portfolio
3.17%
Previous 3.41%
Shares
10 transactions
Others Institutions Holding MRUS
# of Institutions
202Shares Held
61.9MCall Options Held
243KPut Options Held
300K-
Rtw Investments, LP New York, NY4.17MShares$165 Million3.32% of portfolio
-
Commodore Capital LP New York, NY3.35MShares$133 Million14.22% of portfolio
-
Wellington Management Group LLP Boston, MA2.89MShares$114 Million0.03% of portfolio
-
Samlyn Capital, LLC New York, NY2.61MShares$104 Million2.1% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.45MShares$97.3 Million4.42% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $1.82B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...